GENFIT's GNS561 Shows Early Promise in Cholangiocarcinoma Combination Therapy — GENFIT S.A.

Event summary

Phase 1b study of GNS561 in combination with a MEK inhibitor showed favorable safety and tolerability profile in heavily pretreated cholangiocarcinoma patients.
Approximately half of the 19 enrolled patients achieved stable disease at Week 6, with one patient maintaining this status up to Week 30.
Phase 2 initiation remains on track for the second half of 2026, with recommended dose and study design expected to be finalized over the summer.

The big picture

GENFIT's positive Phase 1b data for GNS561 in combination therapy highlights its strategic push into high-unmet-need areas within oncology. The company's focus on cholangiocarcinoma, a rare and aggressive cancer with limited treatment options, aligns with broader industry trends toward precision medicine and combination therapies. With the acquisition of full intellectual property rights for GNS561 and the backing of major investors like Ipsen, GENFIT is positioning itself as a key player in developing innovative treatments for challenging diseases.

What we're watching

Clinical Development: Whether the expanded Phase 1b study at higher dose levels will reinforce early signs of antitumor activity and support the transition to Phase 2.
Regulatory Pathway: The pace at which GENFIT can advance GNS561 through clinical trials given the high unmet need in cholangiocarcinoma.
Strategic Positioning: How GENFIT's focus on rare and life-threatening liver diseases positions it against competitors in the oncology space.